Regeneron Pharmaceuticals and Sanofi's experimental injectable drug dupilumab reduced asthma attacks by 87% during a Phase IIa trial. Patients with moderate to severe asthma who took the drug also experienced improvements in symptoms and lung function. "Overall, these are the most exciting data we've seen in asthma in 20 years," said Sally Wenzel, the trial's lead investigator. The treatment could help move the care of asthma patients toward methods that address the causes of the condition rather than its symptoms, Wenzel said.
Published in Brief: